The Heart Of A Pipeline: Can Novartis Keep The Cardio Portfolio Beating?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The challenge of a generation shift in cardiovascular drugs is not new for Novartis, but the upcoming phase-out of Diovan through 2012 looks more difficult. As the firm prepares to lose Diovan exclusivity, its pipeline reflects an attempt to reprise the time-honored big pharma strategy that carried it through the loss of Lotrel in 2007: mix major efforts to develop novel, first-in-class agents with a push to accelerate its already marketed brands
You may also be interested in...
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.
Efficacy Supplement Numbers On The Rise As Industry Braces For Patent Cliff
Drug makers are squeezing more new and expanded indications out of approved drugs to compensate for patent expiries and the lagging pace of new drug approvals, according to an analysis from the Tufts Center for the Study of Drug Development.
No Sales Model Left Behind: Novartis Joins Firms In Changing Market Focus
Novartis is joining the horde of pharmaceutical companies that are revamping their sales and marketing organizations in response to a U.S. market that is rapidly changing, at varying paces in different regions